# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evolent Health is exploring a potential sale, drawing interest from private equity firms like TPG and KKR.
JP Morgan analyst Lisa Gill maintains Humana (NYSE:HUM) with a Neutral and raises the price target from $332 to $396.
Humana will pay $90 million to settle a whistleblower lawsuit alleging it overcharged the government by submitting fraudulent M...
Cantor Fitzgerald analyst Sarah James reiterates Humana (NYSE:HUM) with a Neutral and maintains $395 price target.
Deutsche Bank analyst George Hill maintains Humana (NYSE:HUM) with a Hold and raises the price target from $341 to $349.